16384 ATI-501, a novel Janus kinase 1/3 inhibitor, demonstrates hair growth in patients with alopecia areata: Results of a phase 2, randomized, double-blind, placebo-controlled trial

Background: There is increasing evidence that inflammatory skin diseases, including AA, involve the JAK/STAT signaling pathway. This trial evaluated the efficacy and safety of ATI-501 in AA patients.